Pharmacokinetics and Antihypertensive Effects of Lisinopril in Hypertensive Patients with Normal and Impaired Renal Function
- 1 October 1990
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Cardiovascular Pharmacology
- Vol. 16 (4) , 594-600
- https://doi.org/10.1097/00005344-199010000-00010
Abstract
The antihypertensive effects and pharmacokinetic properties of lisinopril, an angiotensin-converting enzyme (ACE) inhibitor, were investigated in hypertensive patients with normal renal function (NRF, mean serum creatinine 1.0 mg/dl, n = 9) and those with impaired renal function (IRF, mean serum creatinine 1.7 mg/dl, n = 8). Lisinopril was administered orally (10-mg dose once daily for 5 or 8 days). Measurement of blood pressure (BP) and sampling of blood specimens were made on the first and last days of treatment. During consecutive dosing of lisinopril, its antihypertensive effects were sustained for ≥2 h with less diurnal variation of BP. Serum ACE activity was markedly suppressed for 24 h. Plasma levels of lisinopril in the IRF group were higher than those in NRF with significant differences in the peak levels and areas under the plasma concentration time curve (AUC). A significant inverse correlation was found between the creatinine clearance and the AUC for lisinopril. These results suggest that lisinopril has a long-lasting action and that it is a useful antihypertensive agent for controlling BP in patients with either NRF or mild IRF. When administered for an extended period, however, more careful consideration should be given to the dose in patients with IRF than in patients with NRF to minimize the possibility of untoward side effects.This publication has 11 references indexed in Scilit:
- PHARMACOKINETICS AND ACUTE EFFECT ON THE RENINANGIOTENSIN SYSTEM OF DELAPRIL IN PATIENTS WITH CHRONIC-RENAL-FAILURE1987
- Radioimmunoassay for the Quantitation of Lisinopril and EnalaprilatJournal of Pharmaceutical Sciences, 1986
- Enalapril (MK421) and its lysine analogue (MK521): a comparison of acute and chronic effects on blood pressure, renin-angiotensin system and sodium excretion in normal man.British Journal of Clinical Pharmacology, 1984
- Enalapril maleate and a lysine analogue (MK‐521) in normal volunteers; relationship between plasma drug levels and the renin angiotensin system.British Journal of Clinical Pharmacology, 1982
- Enalapril maleate and a lysine analogue (MK‐521): disposition in man.British Journal of Clinical Pharmacology, 1982
- Pharmacodynamics of converting enzyme inhibition: the cardiovascular, endocrine and autonomic effects of MK421 (enalapril) and MK521.British Journal of Clinical Pharmacology, 1982
- Three new long-acting converting-enzyme inhibitors: Relationship between plasma converting-enzyme activity and response to angiotensin IClinical Pharmacology & Therapeutics, 1981
- Converting enzyme inhibition with an orally active compound in hypertensive man.Hypertension, 1978
- Antihypertensive Effect of the Oral Angiotensin Converting-Enzyme Inhibitor SQ 14225 in ManNew England Journal of Medicine, 1978
- Design of Specific Inhibitors of Angiotensin-Converting Enzyme: New Class of Orally Active Antihypertensive AgentsScience, 1977